Anti–Interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation
Version of Record online: 30 DEC 2003
Copyright © 2001 American Association for the Study of Liver Diseases
Volume 7, Issue 12, pages 1064–1070, December 2001
How to Cite
Nelson, D. R., Soldevila-Pico, C., Reed, A., Abdelmalek, M. F., Hemming, A. W., van der Werf, W. J., Howard, R. and Davis, G. L. (2001), Anti–Interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. Liver Transpl, 7: 1064–1070. doi: 10.1053/jlts.2001.29414
- Issue online: 30 DEC 2003
- Version of Record online: 30 DEC 2003
- National Institutes of Health (D.R.N.). Grant Numbers: K08-DK2595, RO1-HL64817
- 11Quantitative detection of hepatitis C virus RNA by a solid-phase signal amplification method. Definition of optimal conditions for specimen collection and clinical application in interferon-treated patients. Hepatology 1994; 19:1337–1341. MEDLINE, , , , , , et al.
- 14Recent findings concerning liver transplantation in the United States. In: TerasakiPI, CeckaJM (eds). Clinical transplants 1996. Los Angeles: UCLA Tissue Typing Laboratory, 1997:15–30., , .
- 23Changes in hepatitis C virus RNA viremia concentrations in long-term renal transplant patients after introduction of mycophenolate mofetil. Transplantation 2000; 5:991–994., , , , , .
- 25Zenapax and effect on clinical outcome of hepatitis C post liver transplant [abstract]. Gastroenterology 2000; 118:995A., , , , , .